Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Approvals & launches

Roche's Wilserdly gains US clearance; adjuvant decision due 30 November

The US regulator has cleared giredestrant with everolimus for a biomarker-defined breast cancer group, and a second Wilserdly filing faces its review deadline in two weeks.

16 Nov 2026 · Roche · Company news

Roche has secured US marketing clearance for Wilserdly (giredestrant) in a narrow, biomarker-defined breast cancer population, and a second decision on the same drug is due within two weeks. The company announced the first approval on 16 November 2026. The information available gives no price, launch timing or sales expectations.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Approvals & launchesAll →